Could a simple hormone shield kidneys after liver transplant?

NCT ID NCT06344442

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether giving low-dose arginine vasopressin during liver transplant surgery can prevent acute kidney injury, a common complication. Researchers will compare vasopressin to the standard drug norepinephrine in 304 adults. The goal is to see if vasopressin better protects kidney function and reduces the need for dialysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Arginine vasopressin (a hormone that raises blood pressure and may protect the kidneys)
What this could lead to: If it works, this could reduce the risk of kidney failure after liver transplants, lowering the need for dialysis and improving long-term outcomes.
What could go wrong: This is a single phase 3 trial with 304 participants, so results may not apply to all patients. Vasopressin can cause side effects like low sodium or excessive vasoconstriction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY POST LIVER TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY POST LIVER TRANSPLANTATION

Contacts and locations

Locations

URC Lariboisière-Fernand Widal-saint Louis
RECRUITING

Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.